Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-04-01
|
| Series: | Trials |
| Online Access: | https://doi.org/10.1186/s13063-022-06266-0 |
| _version_ | 1818147429621432320 |
|---|---|
| author | Sarah Halford Susan Wan Ilaria Dragoni Julie Silvester Bobojon Nazarov Daniel Anthony Suzie Anthony Emma Ladds John Norrie Kevin Dhaliwal and the CDD SPIKE-1 Project Team |
| author_facet | Sarah Halford Susan Wan Ilaria Dragoni Julie Silvester Bobojon Nazarov Daniel Anthony Suzie Anthony Emma Ladds John Norrie Kevin Dhaliwal and the CDD SPIKE-1 Project Team |
| author_sort | Sarah Halford |
| collection | DOAJ |
| first_indexed | 2024-12-11T12:35:07Z |
| format | Article |
| id | doaj.art-b21f19e815dd45c1a5e94555ef323a1a |
| institution | Directory Open Access Journal |
| issn | 1745-6215 |
| language | English |
| last_indexed | 2024-12-11T12:35:07Z |
| publishDate | 2022-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Trials |
| spelling | doaj.art-b21f19e815dd45c1a5e94555ef323a1a2022-12-22T01:07:09ZengBMCTrials1745-62152022-04-012311110.1186/s13063-022-06266-0Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusionSarah Halford0Susan Wan1Ilaria Dragoni2Julie Silvester3Bobojon Nazarov4Daniel Anthony5Suzie Anthony6Emma Ladds7John Norrie8Kevin Dhaliwal9and the CDD SPIKE-1 Project Team10Cancer Research UK Centre for Drug DevelopmentCancer Research UK Centre for Drug DevelopmentCancer Research UK Centre for Drug DevelopmentCancer Research UK Centre for Drug DevelopmentLatus TherapeuticsUniversity of OxfordOxford University Hospitals NHS Foundation TrustNuffield Department of Primary Care Health Sciences, University of OxfordThe University of EdinburghThe University of EdinburghCancer Research UK Centre for Drug Developmenthttps://doi.org/10.1186/s13063-022-06266-0 |
| spellingShingle | Sarah Halford Susan Wan Ilaria Dragoni Julie Silvester Bobojon Nazarov Daniel Anthony Suzie Anthony Emma Ladds John Norrie Kevin Dhaliwal and the CDD SPIKE-1 Project Team Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion Trials |
| title | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_full | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_fullStr | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_full_unstemmed | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_short | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_sort | correction to spike 1 a randomised phase ii iii trial in a community setting assessing use of camostat in reducing the clinical progression of covid 19 by blocking sars cov 2 spike protein initiated membrane fusion |
| url | https://doi.org/10.1186/s13063-022-06266-0 |
| work_keys_str_mv | AT sarahhalford correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT susanwan correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT ilariadragoni correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT juliesilvester correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT bobojonnazarov correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT danielanthony correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT suzieanthony correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT emmaladds correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT johnnorrie correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT kevindhaliwal correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT andthecddspike1projectteam correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion |